Loading
A phase 2 trial of Lifileucel in melanoma and skin cancer, run by Iovance Biotherapeutics, Inc., active and no longer recruiting.
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is a phase 2 interventional study registered as NCT07288203 by Iovance Biotherapeutics, Inc., with 100 participants planned, started 2025-11-28 and due to reach its primary completion in 2032-12. Interventions recorded: Lifileucel. Conditions listed: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma. No results are recorded here; the registry entry is the source.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Advanced melanoma (unresectable stage III and stage IV).
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Lifileucel, TIL therapy, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.